A Novel Anti-Polysaccharide Antiserum for Detection of Clostridium Difficile Bacteria, and Diagnosis of Clostridium Difficile Colonization in Complex Clinical Specimens

**Title:** A Novel Anti-Polysaccharide Antiserum for Detection of Clostridium difficile Bacteria, and Diagnosis of Clostridium difficile Colonization in Complex Clinical Specimens

**Invention:** The technology is an antiserum that is highly specific for Clostridium difficile. This target is available on all clinically relevant strains of Clostridium difficile bacteria.

**Background:** Clostridium difficile is a bacteria that causes serious intestinal issues. Each year there are approximately 500,000 cases of Clostridium difficile in the United States, which results in $4 billion in healthcare costs. The key to treating this infection and preventing recurrent infections is early, accurate diagnosis. Unfortunately, individuals with a low quantity of Clostridium difficile or non-toxic strains cannot be identified.

**Applications:**
- Diagnostic assays
- Health-systems
- Laboratories

**Advantages:**
- Reduces repeat testing
- Highly specific to Clostridium difficile only

**Licensing Manager:**

Contact Tod McCauley  
Sr. Licensing Manager  
todm@tla.arizona.edu  
(520) 626-7916  

The University of Arizona, Tucson, Arizona
Inventors

Gayatri Vedantam
Professor, 48 Animal & Comparative Biomedical Sciences

Virinchipuram Viswanathan
Associate Professor, SACBC